WO2009066131A1 - Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques - Google Patents
Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques Download PDFInfo
- Publication number
- WO2009066131A1 WO2009066131A1 PCT/IB2007/054691 IB2007054691W WO2009066131A1 WO 2009066131 A1 WO2009066131 A1 WO 2009066131A1 IB 2007054691 W IB2007054691 W IB 2007054691W WO 2009066131 A1 WO2009066131 A1 WO 2009066131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rbcs
- kits
- vaccines
- patients
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 10
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 86
- 239000000427 antigen Substances 0.000 claims abstract description 76
- 108091007433 antigens Proteins 0.000 claims abstract description 76
- 102000036639 antigens Human genes 0.000 claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 244000005700 microbiome Species 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
- 208000026935 allergic disease Diseases 0.000 claims abstract description 7
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 7
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 238000002054 transplantation Methods 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract 2
- 244000045947 parasite Species 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 108010026552 Proteome Proteins 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 9
- 238000007418 data mining Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 3
- 101710164309 56 kDa type-specific antigen Proteins 0.000 claims 6
- 238000009533 lab test Methods 0.000 claims 6
- 238000001709 templated self-assembly Methods 0.000 claims 6
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 4
- 206010064912 Malignant transformation Diseases 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000036212 malign transformation Effects 0.000 abstract description 3
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000003319 supportive effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 230000004520 agglutination Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 201000008827 tuberculosis Diseases 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 241001148106 Brucella melitensis Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 238000001323 two-dimensional chromatography Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Definitions
- RBCs' absorbed antigens will reach the central organ of the immune system (e.g., thymus and bone marrow) and induce central tolerance.
- the degree of induced tolerance is dependant on the size of the RBCs antigens store. In effect, the larger the size of the store, the higher is the probability these antigens meet their corresponding premature lymphocytes in thymus and bone marrow with consequent induction of their apoptosis.
- Antigens are tolerated as far as there are enough stores of those antigens in RBCs. In this way, the degree of immune response to a particular antigen may vary.
- the immune system distinguishes between what is self and what is non- self (foreign body): tolerates self antigens and responds to non-self antigens.
- the phenomenon of tolerating antigens is called immune tolerance or simply tolerance. It can be defined as "a specific unresponsive state induced by prior exposure to an antigen which is due to either a programmed failure of the immune system or active suppression.” Tolerance is a basic function of the immune system that is important to maintain body integrity and health.
- tolerance to self antigens is a process that continues throughout life but begins during fetal development.
- There are a number of mechanisms that describe how tolerance occurs which can be classified into: central, peripheral, and anergy.
- central tolerance immature self -reactive T lymphocytes recognize antigens in the thymus and undergo negative selection (deletion).
- peripheral tolerance mature self- reactive T lymphocytes that escape central tolerance and recognize self antigens in peripheral tissues can be inactivated (anergy), killed (deletion) or regulated (suppressed).
- anergy mature self-reactive lymphocytes do not respond to antigens in non-inflamed environment. Those mechanisms are explained through the following theories: clonal deletion, clonal anergy, clonal ignorance, receptor editing, and suppressor cells.
- RBCs are specialized for transport. Besides, RBCs have pinocytic activity which is well documented. Their cell membrane antigens can function as receptors, e.g., Duffy antigen has been proved to act as a receptor for Plasmodium vivax malaria to invade RBCs. Consequently, RBCs easily absorb soluble antigens through pinocytosis while particulate antigen need receptor sites on RBCs in order to be absorbed. [26] It is important that the discovered function of RBCs fill a gap in understanding of tolerance. Notice that there is a general agreement about this gap. Part of this gap can be expressed in the following questions:
- Blood samples were taken on heparin.
- the lymphocytes were separated using the Ficoll hypaque technique.
- the RBCs were then separated to prepare the hemolysate.
- the hemolysate is prepared by washing RBCs in phosphate buffer saline several times, and then frozen until RBCs are ruptured.
- the fourth is used to detect male spouse HLA antigens in female spouse hemolysate
- the first and second trays are used for typing of HLA Class I for the couple.
- mice • A number of white mice were slaughtered to collect their blood on sodium citrate and their organs (liver, kidney and spleen) were preserved on 10 % formalin.
- RBCs were injected subcutaneously into a number of rabbits for four times on weekly intervals.
- mice were infected by Escherichia coli 0157 through subcutaneous injection. • Mice were slaughtered after 5 days to collect their blood on sodium citrate.
- Rabbits were vaccinated by those RBCs. Rabbits were injected subcu- taneously with one ml on weekly basis for three weeks.
- EBI European Bioinformatics Institute
- NH American National Institute of Health
- HPO Human Proteome Organization
- DM Data Mining in locally built database: DM can be targeted towards the identification of RBCs' proteins related to a particular disease or towards the identification of RBCs' proteins that are missing in a particular disease. Notice that in disorders that are caused by microorganisms, DM may not be essential.
- the invention of new generation of microorganisms' vaccines depends on identifying antigen(s) in RBCs of patients or animals, which belong(s) to a particular microorganism. Antibodies against those antigens will be used in the diagnosis of their corresponding diseases' conditions. Those antibodies can be prepared to be used as passive vaccines, too. In this regard, new technologies, such as Affibody, can be efficiently used to replace natural antibodies.
- Example 1 Preparing a vaccine and diagnostic kits for Tuberculosis
- Mycobacterium tuberculosis is the causative microorganism of tuberculosis disease.
- Collecting blood samples from patients suffering from tuberculosis will enable the identifications of protein(s) related to M. tuberculosis in the samples' RBCs. This is done through the following steps:
- step 2 Use protein(s) identified in step 2 to query public databases.
- the dose and the number of injections that can make an individual immune are to be determined. Also, the interpretation of the titer of the antigen(s) that indicates active TB, immunity, or exposure is to be determined.
- the monoclonal antibodies against this active vaccine can be packaged as kits suitable for different laboratory equipment (e.g., ELISA, Flowcytometry, etc.).
- Example 2 Preparing vaccines and diagnostic kits for a malignant tumor
- Every type of malignancy has its specific tissue antigens.
- a group of tumors may share (a) specific tissue antigen(s). Consequently, collecting blood samples from patients suffering from the same type of tumor will enable the identification of malignancy antigen(s) of that tumor. The use of data mining will be very helpful. It will enable the identification of malignant tissue antigens that are shared between a group of tumors. If the proteome of the malignant tumor is known, then steps similar to "Example I" can be applied. Consequently, the steps done are:
- the monoclonal antibodies against this active vaccine can be packaged as diagnostic kits suitable for different laboratory equipment (e.g., ELISA, Flowcytometry, etc.).
- diagnostic kits suitable for different laboratory equipment e.g., ELISA, Flowcytometry, etc.
- Example 3 Preparing diagnostic kits and treatment components for autoimmune disorders and chronic rejection syndrome
- step 2 Use proteins identified in step 2 to query public databases so that tissues or organs of these proteins may be determined.
- FIG. 1 depicts the methods of preparing different products for humans. These methods can be described in the following steps:
- the main resource is the RBCs samples of patients and normal individuals.
- the sample proteome is stored in the local database.
- the proteins that are found in a particular disease are used to query external databases storing human proteomes, microorganism proteomes, and other proteomes.
- the disease related proteins are used in methods of antibodies preparation and vaccine preparation.
- the proteins that are found in normal individuals and identified are used in methods of antibody preparation and component preparation.
- Diagnostic kits are produced using prepared antibodies, if proteins exist in RBCs of patients. If proteins do not exist in patients and exist in normal individual, diagnostic kits are prepared from prepared components to detect circulating antibodies.
- Fig. 2 depicts the methods of preparing different products for animals.
- animals we mean the dictionary definition: "A multicellular organism of the kingdom Animalia, differing from plants in certain typical characteristics such as capacity for locomotion, nonphotosynthetic metabolism, pronounced response to stimuli, restricted growth, and fixed bodily structure.”
- the sample proteome is stored in the local database.
- the proteins that are found in a particular disease are used to query external databases storing microorganism proteomes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rehabilitation Therapy (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des procédés de production d'un certain nombre de produits. Ces produits comprennent des vaccins, des nécessaires de laboratoire clinique et des composants thérapeutiques. Les produits vaccinaux comprennent des vaccins contre les bactéries, les virus et les parasites chez l'être humain et l'animal, ainsi que des vaccins prévenant la formation de tumeurs malignes chez des patients présentant une évolution maligne ou encore des vaccins constituant un traitement d'appoint chez des patients souffrant déjà d'une tumeur. Les nécessaires de laboratoire clinique comprennent des nécessaires de diagnostic permettant un diagnostic efficace de maladies provoquées par des micro-organismes chez l'homme et l'animal ; des nécessaires de diagnostic de tumeurs malignes ; des nécessaires de typage tissulaire pour les greffes d'organes ; et des nécessaires de suivi du rejet et de l'hypersensibilité en cas de greffe. Les composants thérapeutiques contribueront au traitement de troubles complexes, notamment, par exemple, les troubles d'hypersensibilité, le rejet de greffe chronique et les affections auto-immunes. En effet, les produits pouvant être obtenus sur la base de la présente découverte sont innombrables. Les procédés de l'invention sont fondés sur notre découverte d'une nouvelle fonction des globules rouges : leur capacité à transporter de façon sélective des auto-antigènes et antigènes étrangers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2007/054691 WO2009066131A1 (fr) | 2007-11-19 | 2007-11-19 | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2007/054691 WO2009066131A1 (fr) | 2007-11-19 | 2007-11-19 | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009066131A1 true WO2009066131A1 (fr) | 2009-05-28 |
Family
ID=39232777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2007/054691 WO2009066131A1 (fr) | 2007-11-19 | 2007-11-19 | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009066131A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012059112A1 (fr) * | 2010-11-01 | 2012-05-10 | Mahmoud Abdel Wahed Rafea | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000014547A1 (fr) * | 1998-09-04 | 2000-03-16 | Powderject Research Limited | Immunodiagnostics au moyen de procedes d'administration de particules |
| US6632599B1 (en) * | 1997-12-19 | 2003-10-14 | Dade Behring Marburg Gmbh | Detection and determination of solid phase-associated factors |
| WO2006031544A2 (fr) * | 2004-09-09 | 2006-03-23 | New England Medical Center Hospitals, Inc. | Methodes de detection d'agents pathogenes dans des erythrocytes |
-
2007
- 2007-11-19 WO PCT/IB2007/054691 patent/WO2009066131A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632599B1 (en) * | 1997-12-19 | 2003-10-14 | Dade Behring Marburg Gmbh | Detection and determination of solid phase-associated factors |
| WO2000014547A1 (fr) * | 1998-09-04 | 2000-03-16 | Powderject Research Limited | Immunodiagnostics au moyen de procedes d'administration de particules |
| WO2006031544A2 (fr) * | 2004-09-09 | 2006-03-23 | New England Medical Center Hospitals, Inc. | Methodes de detection d'agents pathogenes dans des erythrocytes |
Non-Patent Citations (12)
| Title |
|---|
| BRUSCHI MAURIZIO ET AL: "Proteomic analysis of erythrocyte membranes by soft immobiline gels combined with differential protein extraction", JOURNAL OF PROTEOME RESEARCH, vol. 4, no. 4, July 2005 (2005-07-01), pages 1304 - 1309, XP002485634, ISSN: 1535-3893 * |
| JONES, D.R.E. ET AL: "An enzyme-linked immunosorbent assay for complement regulatory proteins and membrane-bound immunoglobulins on intact red blood cells", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 177, 1994, pages 235 - 242, XP002514930 * |
| MAHONEY D F ET AL: "Bovine babesiosis: the immunization of cattle with fractions of erythrocytes infected with Babesia bovis (syn B. argentina).", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY APR 1981, vol. 2, no. 2, April 1981 (1981-04-01), pages 145 - 156, XP002485631, ISSN: 0165-2427 * |
| MEICHENIN M ET AL: "Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation1", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 60, 1 October 2000 (2000-10-01), pages 5499 - 5507, XP002960527, ISSN: 0008-5472 * |
| NYDEGGER URS E ET AL: "Histo-blood group antigens as allo- and autoantigens.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES JUN 2005, vol. 1050, June 2005 (2005-06-01), pages 40 - 51, XP002514928, ISSN: 0077-8923 * |
| PASINI ERICA M ET AL: "In-depth analysis of the membrane and cytosolic proteome of red blood cells.", BLOOD 1 AUG 2006, vol. 108, no. 3, 1 August 2006 (2006-08-01), pages 791 - 801, XP002514931, ISSN: 0006-4971 * |
| SHEN C -R ET AL: "Characterization of the dominant autoreactive T-cell epitope in spontaneous autoimmune haemolytic anaemia of the NZB mouse", JOURNAL OF AUTOIMMUNITY 200203 GB, vol. 18, no. 2, March 2002 (2002-03-01), pages 149 - 157, XP002485632, ISSN: 0896-8411 * |
| SIEGEL D L: "The human immune response to red blood cell antigens as revealed by repertoire cloning", IMMUNOLOGIC RESEARCH, HUMANA PRESS, INC, US, vol. 17, no. 1-2, 1 January 1998 (1998-01-01), pages 239 - 251, XP009112069, ISSN: 0257-277X * |
| SPRINGER, G. F.: "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis and immunotherapy", J MOL MED, vol. 75, 1997, USA, pages 594 - 602, XP002514927 * |
| TALAMO FABIO ET AL: "Proteins from bovine tissues and biological fluids: defining a reference electrophoresis map for liver, kidney, muscle, plasma and red blood cells.", PROTEOMICS APR 2003, vol. 3, no. 4, April 2003 (2003-04-01), pages 440 - 460, XP002485633, ISSN: 1615-9853 * |
| URBANIAK STANISLAW J ET AL: "Peptides Derived from the RhD Protein Generate Regulatory Cytokines In Vitroand Induce Mucosal Tolerance to RhD in HLA-DR15 Transgenic Mice", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, vol. 100, no. 11, 16 November 2002 (2002-11-16), pages AbstractNo.81, XP009098309, ISSN: 0006-4971 * |
| YARED, M.A. ET AL: "Stable solid-phase Rh antigen", TRANSFUSION MEDICINE, vol. 7, 1997, pages 311 - 317, XP002514929 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012059112A1 (fr) * | 2010-11-01 | 2012-05-10 | Mahmoud Abdel Wahed Rafea | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diamond et al. | The demonstration of anti-Rh agglutinins—an accurate and rapid slide test | |
| Hamilton | Assessment of human allergic diseases | |
| Rocklin et al. | Factors that modify the cellular-immune response in patients infected by Schistosoma mansoni. | |
| EVANS et al. | The serology of autoimmune hemolytic disease: observations on forty-one patients | |
| Ahmed et al. | Biology of disease | |
| Jafari et al. | Immunohistochemical observation of local inflammatory cell infiltration in the host-tissue reaction site of human hydatid cysts | |
| CN103698511A (zh) | 结核分支杆菌蛋白在制备诊断潜伏性肺结核感染的产品中的用途 | |
| Quillen et al. | Screening plateletpheresis donors for HLA antibodies on two high‐throughput platforms and correlation with recipient outcome | |
| Evers et al. | Absence of the spleen and the occurrence of primary red cell alloimmunization in humans | |
| Coovadia et al. | Alterations in immune responsiveness in acute measles and chronic post-measles chest disease | |
| EP2453243A1 (fr) | Procédé pour le diagnostic et/ou le suivi de l'évolution d'une tumeur | |
| Ismail et al. | Detection and characterization of Leishmania in tissues of patients with post kala-azar dermal leishmaniasis using a specific monoclonal antibody | |
| Hu et al. | Expression of human leukocyte antigen-G and acute rejection in patients following liver transplantation | |
| WO2009066131A1 (fr) | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques | |
| Smael et al. | Association of Rhesus blood group (RhD) and toxoplasmosis in women with miscarriage in Erbil | |
| WO2012059112A1 (fr) | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes | |
| Schroeder et al. | Spontaneous basophil responses in food-allergic children are transferable by plasma and are IgE-dependent | |
| Vider et al. | Carcinoembryonic antigen (CEA) monitoring in the management of radiotherapeutic patients | |
| Bligh et al. | Serological analysis of the outcome of treatment of Schistosoma mansoni infections with praziquantel | |
| Hackett et al. | Serum detection of carcinoma | |
| Houba et al. | Rheumatoid arthritis in Kenya. II. Serological observations. | |
| Homburger et al. | Diagnosis of allergy: in vitro testing | |
| Barbosa et al. | Biological and cultural determinants of immunoglobulin levels in a Brazilian population with Chagas' disease | |
| Rafea et al. | Rediscovering Red Blood Cells: Revealing Their Dynamic Antigens | |
| Maurer | Cold Agglutinins and Cryoglobulins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07849176 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07849176 Country of ref document: EP Kind code of ref document: A1 |